Royalty Pharma Declares Third Quarter 2025 Dividend
Rhea-AI Summary
Royalty Pharma (Nasdaq: RPRX) has announced its quarterly dividend payment for Q3 2025. The company will distribute a dividend of $0.22 per Class A ordinary share. The dividend is scheduled to be paid on September 10, 2025, to shareholders who are registered as of the record date on August 15, 2025.
Positive
- Consistent dividend payment demonstrates commitment to shareholder returns
Negative
- None.
News Market Reaction – RPRX
On the day this news was published, RPRX gained 0.34%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
NEW YORK, July 18, 2025 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2025 of
The dividend will be paid on September 10, 2025, to shareholders of record at the close of business on August 15, 2025.
About Royalty Pharma
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 16 development-stage product candidates. For more information, visit www.royaltypharma.com.
Royalty Pharma Investor Relations and Communications
+1 (212) 883-6637
ir@royaltypharma.com
FAQ
What is Royalty Pharma's (RPRX) dividend amount for Q3 2025?
When is the dividend payment date for Royalty Pharma's Q3 2025 dividend?
What is the record date for Royalty Pharma's Q3 2025 dividend?
What type of shares are eligible for Royalty Pharma's Q3 2025 dividend?
